Day 11 FGI: 38

(NASDAQ:AAPL) lost its status as the best-selling smartphone brand in the crucial Chinese market last year, new data showed Thursday, with a pair of local rivals surpassing it with surging shipments. The California-based tech giant claimed a market share of 15 percent in the world's number two economy, behind Huawei's 16 percent and top-ranking Vivo's 17 percent, according to industry data provider Canalys.

Taiwan took another step in enhancing its key role in the production of advanced semiconductor chips used for artificial intelligence on Thursday with the inauguration of a new plant by Siliconware Precision Industries Co. The opening ceremony for the Tan-Ke factory in the central city of Taichung was attended by Jensen Huang, CEO and co-founder of California-based Nvidia Corp., a world leader in the design of AI chips, reinforcing the companies' partnership in the production of advanced AI chips. SPIL is a leader in semiconductor packaging and testing. 'The technology that we're working on is becoming more sophisticated. Chips are getting more and more complex, and the packaging technology will need to evolve as well. What's even more exciting is the integration of silicon photonics, enabling us to connect multiple packages into one massive system,' Huang said. He said Nvidia's partnership with SPIL would be instrumental in pushing the boundaries of innovation in the coming years.

Day 10 FGI: 28

Biomerica, Inc. (NASDAQ:BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel Prostate Specific Antigen (PSA) Screening Test has received approval from the United Arab Emirates Ministry of Health and Prevention (MOHAP). The Fortel PSA Screening Test is a user-friendly diagnostic tool that provides accurate results in just 10 minutes using a simple finger-prick blood sample. By measuring elevated PSA levels, a recognized early marker of prostate disease, the test can enable early detection of prostate cancer and other prostate-related conditions. This rapid and accessible approach aims to enhance proactive health management, reduce the burden on healthcare systems, and improve patient outcomes.

UnitedHealth Group (NYSE:UNH) reported quarterly earnings of $6.81 per share which beat the analyst consensus estimate of $6.72 by 1.34 percent. The company reported quarterly sales of $100.81 billion which missed the analyst consensus estimate of $101.76 billion by 0.94 percent. This is a 6.76 percent increase over sales of $94.43 billion the same period last year. UnitedHealth Group Affirms 2025 Outlook With Sales Of $450B-$455B And Adjusted EPS Of $29.50-$30.00 Compared To Consensus Of $448.125B And $29.83, Respectively And Cash Flow From Operations Of $32B-$33B

Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company's previously announced sale of its VOWST business to Societe des Produits Nestle S.A (SPN, and with certain of its affiliates, collectively, Nestle Health Science). This installment payment was expected as Seres is fulfilling its transition obligations. As previously announced, based on the Company's existing cash, inclusive of this payment, a projected installment payment from Nestle Health Science in July 2025 of $25 million (less up to approximately $1.5M in employment-related payments to Nestle Health Science), transaction-related obligations and current operating plans, the Company expects to fund operations into the first quarter of 2026.

Shares of US Bancorp (USB) plunged 5.6%. The move lower came after the financial services firm reported mixed quarterly results, topping adjusted profit estimates but falling short of forecasts for its net interest margin, a key measure of a bank's effectiveness in lending its capital.

Texas Instruments (TXN) shares sank 5.1% after reports that China's Commerce Ministry is launching an investigation into the legality of U.S. subsidies for chipmakers that create competitive challenges for Chinese products. With a focus on lower-end semiconductors like power and analog chips, Texas Instruments could face repercussions if Chinese officials determine the company has violated anti-dumping regulations.

Shares of Dexcom (DXCM), a manufacturer of glucose-monitoring devices for patients with diabetes, gained the most of any S&P 500 stock on Thursday, jumping 5.5%. Analysts at Piper Sandler highlighted several bullish catalysts for Dexcom, including a stable outlook for its durable medical equipment (DME) channel and the approval of reimbursement for 5 million patients with type 2 diabetes who do not use insulin. In addition, Baird analysts boosted their price target on Dexcom stock, noting improvements in salesforce productivity and growth potential in U.S. markets.

JPMorgan boosted its price target on Estee Lauder (EL) stock, and shares of the makeup and skin-care specialist jumped 4.8%. Analysts said they expect this earnings season to be consequential for makers of household and personal-care products, with discussions about consumer behaviours, tariff risks, currency impacts, and interest-rate expectations likely to influence the 2025 industry outlook.

Semiconductor equipment stocks advanced after Taiwan Semiconductor Manufacturing Co. (TSM), issued strong fourth-quarter profit guidance. The world's largest contract chipmaker highlighted an upbeat outlook for artificial intelligence (AI) demand, which bodes well for sales of chip manufacturing gear, even as the Netherlands announced tightened export rules that could affect the industry. Shares of Applied Materials (AMAT), KLA Corp. (KLAC), and Lam Research (LRCX) shares gained 4.5%, 4.3%, and 4.0%, respectively.

Day 9 - FGI: 29 #Quantum #Robotics

In December, the Consumer Price Index for All Urban Consumers rose 0.4 percent, seasonally adjusted, and rose 2.9 percent over the last 12 months, not seasonally adjusted. The index for all items less food and energy increased by 0.2 percent in December (SA), up 3.2 percent over the year (NSA).

China's central bank injected a near record-high amount of liquidity into the banking system to help meet demand for cash even as it looks to support the yuan.

(NASDAQ:MSFT) 2025: The year to become Quantum-Ready

Day 8 - FGI: 26

Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the advancement of research to assess a patient's brain age - an estimation of the biological age of a person's brain - via its FDA-cleared BNA technology platform. 64.73%

Applied Digital (APLD) shares jumped in intraday trading Tuesday after it announced that Macquarie Asset Management will invest up to $5 billion in its high-performance computing (HPC) data centers.

Nvidia (NVDA) has already invested in its data centers and last year announced a stake in the company, which provides advanced digital infrastructure designed to support high-performance computing and artificial intelligence applications.

Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year. The maker of weight-loss drugs Mounjaro and Zepbound said sales of the drugs grew slower than expected in the fourth quarter, along with lower-than-expected inventory of the products. Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs over the first half of this year compared to 2024. The drugmaker said it anticipates revenue between $58 billion to $61 billion in fiscal 2025, while analysts currently project $59.33 billion. The company said it plans to report fourth-quarter earnings and outline its full forecast for fiscal 2025 on Feb. 6. Eli Lilly shares were down nearly 7% Tuesday afternoon following the news, though even with Tuesday's losses, they've gained over 15% in the last 12 months.

Boeing (BA) was the worst-performing stock in the Dow Jones Industrial Average Tuesday after the American plane maker's fourth-quarter 2024 deliveries revealed a widening gap with European rival Airbus. Boeing delivered 57 commercial planes in Q4 and 348 for the full year, down from 157 and 528, respectively, a year ago. By contrast, Airbus recently reported 269 deliveries in the fourth quarter and 766 in 2024, its highest full-year total since 2019. Airbus. "Orders and deliveries." Boeing's fourth-quarter production was impacted by a nearly two-month strike by its union machinists, which was resolved in November with a new contract agreement. Boeing is still trying to find its footing a year after an Alaska Airlines (ALK) flight aboard a 737 MAX plane had a door panel detach in midair. Earlier this month, outgoing Federal Aviation Administration (FAA) head Mike Whitaker said the plane maker's safety turnaround plan is "not a one-year project." Shares of Boeing traded 2% lower Tuesday afternoon and have lost nearly a quarter of their value over the past year. The company will report its fourth-quarter results on Jan. 28.

KB Home (KBH) shares climbed Tuesday, a day after the home builder reported better-than-expected results as deliveries jumped. The company posted fourth-quarter earnings per share (EPS) of $2.52, with revenue up 19% from a year ago to $2 billion. Both figures exceeded analysts' forecasts compiled by Visible Alpha. Homes delivered increased 17% to 3,978, and the average selling price rose 3% to $501,000. Homebuilding operating income grew 27% to $229.1 million, and homebuilding operating margin added 60 basis points (bps) to 11.5%. CEO Jeffrey Mezger said the boost in deliveries was driven by faster construction times. He noted that new orders climbed by about 40% on continuing demand and improved market conditions, "despite ongoing mortgage interest rate headwinds." Mezger added that the company spent more than $2.8 billion in 2024 on land purchases and development, and "we plan to increase our investment again in 2025." KB Home shares were up about 3% Tuesday afternoon and have added about 10% over the past 12 months.

H&E Equipment Services (HEES) shares more than doubled in value intraday Tuesday after the company reached a deal to be acquired by United Rentals (URI) for $4.8 billion. United Rentals. "United Rentals to Acquire H&E Equipment Services, Inc." The purchase price equates to $92 per share, and H&E stock vaulted accordingly to $90.51 intraday Tuesday. Shares of United Rentals rose close to 4%. The combination of equipment renters expands United Rentals' fleet by nearly 64,000 units and is expected to generate roughly $130 million in annual cost synergies within two years of the deal closing. The combined company's equipment rental offerings will include power and HVAC, portable storage, tool solutions, fluid solutions, and more. H&E generated adjusted EBITDA of $696 million on revenue of $1.52 billion in the 12 months ended Sept. 30. The transaction, which also includes $1.4 billion of net debt, is expected to close in the first quarter of 2025, the company said.

Shares of Jared, Zales, and Kay Jewelers parent Signet Jewelers (SIG) plunged 22% Tuesday after the biggest diamond jewelry retailer cut its guidance on weak holiday demand. Signet's preliminary same-store sales for the 10 weeks ending Jan. 11 were down about 2%, pointing to "peak selling days leading up to Christmas that were below forecast," Chief Financial and Operating Officer Joan Hilson said. Hilson noted that "fashion gifting underperformed as consumers gravitated to lower price points even more than anticipated in a continued competitive environment." Hilson added that while the merchandise margin was up, it rose less than expected because of a "lower fashion mix and a stronger customer response to promotional items." Because of the results, Signet lowered its fourth-quarter sales estimate to $2.32 billion to $2.335 billion from the previous outlook of $2.38 to $2.46 billion. It sees same-store sales down 2.5% to 2.0%, reduced from the earlier prediction of flat to 3% higher. Signet Jewelers shares sank to their lowest level since October 2022.

BP (BP) stock fell in early trading Tuesday after the British oil giant said it expects to book impairments of between $1 billion and $2 billion in the fourth quarter. BP. "Fourth quarter 2024 trading statement." The company said in a fourth-quarter trading update that the "non-cash, post-tax charges" were attributable across its units. It also said that its upstream production is expected to be lower than that in the third quarter when output was 2.4 million oil-equivalent barrels per day. The firm also said it expects "weaker" fourth-quarter margins on its refining business. BP's U.S.-listed shares fell about 1% at the open, but have risen about 5% this year amid higher oil prices.

Day 7 - FGI: 27

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2 patients with a complete response or 100% tumor clearance. 292.89%

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and Decoy Therapeutics, Inc., a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announce the signing of a definitive agreement under which Decoy Therapeutics will merge with a wholly-owned subsidiary of Salarius Pharmaceuticals, subject to the closing conditions set forth in the definitive agreement. The newly formed company will be named Decoy Therapeutics. 135.14%

Major U.S. equities indexes were mixed to start a new trading week ahead of inflation data that could provide some clarity on the interest-rate outlook for 2025. Earnings reports from the largest U.S. banks are also set for release this week.

After trading in negative territory for most of the day, the S&P 500 rallied in the afternoon to close Monday's session with a gain of 0.2%. The Dow was up 0.9%, while the tech-heavy Nasdaq slipped 0.4%.

Shares of Mosaic (MOS) jumped 8%, the most of any S&P 500 stock, as the fertilizer maker announced an agreement to sell its Patos de Minas phosphate mine in Brazil to a local operator. A report published last week by Zacks Equity Research suggested that Mosaic is poised to benefit from upbeat phosphate and potash demand trends as well as cost-cutting initiatives aimed at navigating a challenging environment for fertilizer prices.

It was also a positive day for shares of fellow agricultural nutrients manufacturer CF Industries (CF), as investment bank Piper Sandler upgraded the stock to "overweight" from "underweight." CF stock rose 7.6% as analysts predicted that reduced grain production in the U.S. and an improving outlook for grain prices would help underpin strong pricing in the company's key nitrogen fertilizer market.

Diagnostics and life sciences firm Revvity (RVTY) said it had received regulatory approval for its automated test for measuring free testosterone levels. The company also announced a neonatal sequencing research partnership with Element Biosciences. Revvity shares gained 7.8%.

Shares of healthcare companies with exposure to managed care plans moved higher Monday following last week's proposal by the U.S. government to boost Medicare Advantage reimbursement rates by more than 4% in 2026. Shares of CVS Health (CVS) jumped 7.3%, while Humana (HUM) shares were up 6.8%.

Biotech and pharma giant Moderna (MRNA) slashed its 2025 sales guidance by $1 billion, noting it expects revenue to be weighted toward the second half of the year and to be generated primarily by its COVID-19 and respiratory syncytial virus vaccines. Although Moderna also announced plans to cut costs by $1 billion this year and another $500 million in 2026, its shares plunged 16.8%, the steepest loss in the S&P 500.

Macy's (M) stock sank after the biggest U.S. department store chain warned fourth-quarter sales would be at or below earlier estimates because of poor results from underperforming locations.

As tragic wildfires devastate Southern California, shares of area electric utility Edison International (EIX) extended the heavy declines posted last week, dropping 11.9% on Monday. Fire agencies are reportedly investigating whether electrical equipment from subsidiary Southern California Edison's could have played a role in igniting the Hurst Fire.

Shares of Valero Energy (VLO) and rival oil producers rose as new U.S. sanctions on Russian crude sent futures to their highest level since last summer.

Shares of Humana (HUM) and other health insurance providers jumped on indications the U.S. may increase payments for Medicare Advantage plans in 2026.

Sage Therapeutics (SAGE) shares took off after Biogen (BIIB) offered to buy the rest of the Sage stock it doesn't already own for $7.22 per share.

Constellation Energy (CEG) shares sank 8.5%, reversing some of Friday's surge of more than 25% posted by the stock after the energy producer announced an agreement to acquire rival Calpine. The $26.6 billion deal expands Constellation's footprint in California and Texas, and the company said the combination will create the largest clean energy provider in the U.S.

Gold prices fell. The yield on the 10-year Treasury note gained. The U.S. dollar was up on the euro and pound but edged lower against the yen. Most major cryptocurrencies traded lower.

Week 2

Day 6

NVDA CES keynote recap

U.S. equities tumbled at midday as a stronger-than-expected December jobs report raised concerns that the Federal Reserve will hold back on future interest-rate cuts. The Dow Jones Industrial Average, S&P 500, and Nasdaq all dropped around 2%.

Constellation Brands (STZ) was the worst-performing stock in the S&P 500 after the maker of beer, wine, and spirits slashed its guidance on lower consumer spending.

Shares of Allstate (ALL) and rival insurers dipped as estimates show that wildfires in California could cause up to $150 billion in damages.

AbbVie (ABBV) shares declined when the biotech company reported it would take approximately $3.5 billion in an impairment charge due to the failure of a schizophrenia drug in a Phase 2 trial.

Delta Air Lines (DAL) shares flew higher when the airline gave a better-than-expected outlook, and CEO Ed Bastian said 2025 would be the carrier's best year ever.

Shares of Walgreens Boots Alliance (WBA) jumped after the drugstore chain beat profit and sales estimates on cost-cutting measures.

Air Products and Chemicals (APD) shares advanced when proxy advisor Glass Lewis called on shareholders to vote for board candidates backed by activist investor Mantle Ridge, which is demanding a major overhaul of the industrial gases provider.

In stocks, two issues triggered sell signals. Aris Water Solutions (ARIS) and OSI Systems (OSIS) fell below their 50-day moving average in heavy volume.

Health care stocks weighed on the Dow. Merck (MRK) and Johnson & Johnson (JNJ) fell 2% each.

Another Dow stock, Nvidia, rose 2% at the open but quickly erased those gains. About one hour into the session, shares were up 0.3%. The stock is trying to turn resistance at the 50-day line into a support level. In morning trading, shares held above the line.

Quantum computing stocks tumbled further on Wednesday. D-Wave Quantum (QBTS) and IonQ (IONQ) dived nearly 40% each, giving up much of their recent gains. IonQ undercut its 50-day moving average in heavy volume. The drop comes after Nvidia Chief Executive Jensen Huang said late Tuesday that quantum computing could take at least 15 years to become useful.

SolarEdge (SEDG) fell after Citigroup downgraded the stock to sell from neutral with a price target of 9. SolarEdge has been trending lower for a year and a half.

Instacart parent Maplebear (CART) jumped nearly 5%, clearing the 50-day moving average as it forms a cup base, on news that it will join the S&P MidCap 400 index.

Shares of Cal-Maine (CALM) moved higher on earnings. Sales of $954.7 million and earnings of $4.47 per share easily beat estimates of $751.5 million and $4.05, respectively. A seasonal boost in demand for eggs and higher prices amid a bird flu outbreak helped sales.

In economic news, the ADP jobs report showed private payrolls rose 122,000 in December but missed estimates of 134,000. Initial jobless claims of 201,000 were lower than the consensus estimate of 216,000. The yield on the benchmark 10-year Treasury note was flat at 4.68% — still up near an April high.

Oil futures took off on new U.S. sanctions on Russian crude. Gold prices rose. The U.S. dollar was up on the euro and pound, but lost ground to the yen. Most major cryptocurrencies were up.

01/07 SoundHound AI, Inc. (Nasdaq: SOUN) unveiled the first ever in-vehicle voice commerce platform with a demo at CES 2025. The platform, which allows drivers and passengers to order takeout for pick-up directly from the car’s infotainment system, will be showcased in SoundHound’s CES booth at the Las Vegas Convention Center.

01/03 Apple Fitness+ unveils an exciting lineup of new ways to stay active and mindful in
2025

01/02 PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference

01/02 SOUN announced that Lucid, maker of the world's most advanced electric vehicles, has launched the Lucid Assistant.

01/02 TSLA reporting sales of 495,570 electric vehicles in the fourth quarter and of 1.789 million for all of 2024, falling slightly short of Wall Street estimates and, in a first for the company, lagging the previous year's total.

12/30 Joby Successfully Conducts First FAA Testing under TIA, Begins Final Phase of Certification Program Program

12/30 IonQ and Oak Ridge National Laboratory Unveil Novel Approach to Scalable Quantum Computing

12/26 Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

12/26 Crown CEO Issues Update Letter to Shareholders

12/23 Eco Wave Power Global AB (publ) (Nasdaq: WAVE) (“Eco Wave Power” or the “Company”), a global leader in onshore wave energy technology, is pleased to announce that its Founder and CEO, Inna Braverman, will be speaking at Imagination In Action 2025: Architects of the Global Future, on the 22nd of January, 2025. This prestigious event, held in alignment with the World Economic Forum’s Annual Meeting in Davos, Switzerland, underscores her leadership in sustainable innovation and renewable energy.

12/20 Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

12/19 Richtech Robotics to Showcase Latest Service Robotics Innovations at CES 2025, Featuring AI-Driven Scorpion Robot and New Delivery Robots

12/12 Costco Wholesale Corporation Reports First Quarter Fiscal Year 2025 Operating Results

12/05 Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication

12/03 Microsoft Corp. on Tuesday announced that its board of directors declared a quarterly dividend of $0.83 per share. The dividend is payable March 13, 2025, to shareholders of record on Feb. 20, 2025. The ex-dividend date will be Feb. 20, 2025.

12/02 Nauticus Robotics, Inc. (NASDAQ: KITT), a leading innovator in autonomous subsea robotics and software, recently completed a project for a second global supermajor oil and gas company in the Gulf of Mexico (GOM) to perform a subsea field inspection utilizing its flagship underwater vehicle, Aquanaut Mark 2.

11/20 NVIDIA (NASDAQ: NVDA) today reported revenue for the third quarter ended October 27, 2024, of $35.1 billion, up 17% from the previous quarter and up 94% from a year ago. For the quarter, GAAP earnings per diluted share was $0.78, up 16% from the previous quarter and up 111% from a year ago. Non-GAAP earnings per diluted share was $0.81, up 19% from the previous quarter and up 103% from a year ago.

10/29 First Solar, Inc. Announces Third Quarter 2024 Financial Results

NEWSMAX raises $135 million for pre-IPO plan.

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, and Shanghai Jemincare Pharmaceutical Co., Ltd ("Jemincare"), a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China, today announced they have entered into an exclusive license agreement for JYB1904 (RAPT designation RPT904), a clinical-stage, half-life extended anti-immunoglobulin E (IgE) monoclonal antibody. Under the terms of the license agreement, RAPT is granted worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan (together, the "Jemincare Territory") to develop and commercialize RPT904. As consideration for the license, Jemincare receives a $35 million upfront license fee, up to $672.5 million in additional payments upon the achievement of various regulatory and commercial milestones, and royalties on future sales of RPT904 outside the Jemincare Territory. RPT904 is being developed to offer patients a potentially improved therapeutic option compared to omalizumab (marketed as Xolair®), an anti-IgE monoclonal antibody approved for several allergic disorders, including asthma, chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps and, most recently, food allergy. RAPT plans to pursue development of RPT904 initially in food allergy. Separately, Jemincare is conducting Phase 2 clinical trials of JYB1904 in China in asthma and CSU.

W50

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 / Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the successful outcome of recent written and oral communication with the U.S. Food and Drug Administration (FDA) that provides a clear and well-defined regulatory pathway for the Viaskin Peanut patch program in toddlers 1 - 3-years-old. The FDA has formalized guidance on an Accelerated Approval for the Viaskin Peanut patch in toddlers 1 - 3-years-old. DBV and FDA have agreed on the key design elements for a post-marketing confirmatory study.(NASDAQ:DBVT)

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS (NASDAQ:BCTX)

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival. (NASDAQ:CADL)

Metagenomi shared closed after an analyst report from Jefferies, which assigned a 'Buy' rating and set a price target of $21, indicating a potential upside of over 1,000%. The report highlights Metagenomi's advancements in gene editing, particularly the durable Factor VIII activity levels achieved in non-human primate studies for their hemophilia A treatment, MGX-001. Additionally, the company's collaborations, such as with Ionis Pharmaceuticals on RNA-targeted therapeutics, further bolster investor confidence. (NASDAQ:MGX)

Chimerix announced plans to submit a New Drug Application (NDA) for dordaviprone, targeting recurrent H3 K27M-mutant diffuse glioma, before year-end following collaborative discussions with the FDA. If approved, dordaviprone would be the first therapy for this aggressive brain cancer, with potential U.S. launch as early as 3Q 2025. Clinical data highlighted a 28% objective response rate, median response duration of 10.4 months, and significant reduction of the hallmark mutation. A Priority Review request is also planned, which could expedite the FDA review process. (NASDAQ:CMRX)

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial (NASDAQ:SONN)

LeddarTech Announces Collaboration with Texas Instruments for Advanced Driver Assistance Systems and Autonomous Driving Solutions (NASDAQ:LDTC)

W49

Protara Therapeutics reported positive Phase 2 results for TARA-002 in NMIBC, achieving a 72% six-month complete response rate, 100% CR in BCG-unresponsive patients, and no severe adverse events, with durable responses up to six months; 12-month data anticipated mid-2025. Shares closed the week up 96% at $5.91. (NASDAQ:TARA)

Senti Biosciences, Inc. reported initial Phase 1 data for SENTI-202 in relapsed/refractory hematologic malignancies, with 2 of 3 patients achieving MRD-negative CR and a favorable safety profile, while raising $16.7M via a PIPE deal through Series A Convertible Preferred Stock. Shares closed the week up 156% at $5.5. (NASDAQ:SNTI)

Maxim Group analyst Michael Okunewitch initiates coverage on Citius Oncology with a Buy rating and announces Price Target of $3. (NASDAQ:CTOR)

Shimmick awarded $45.4M contract to complete Murray Street Bridge project. (NASDAQ:SHIM)

Janux Therapeutics announced positive updated interim clinical data for its JANX007 clinical program. "These clinical data show substantial. (NASDAQ:JANX)

Cheetah Net Supply Chain Service Inc. today announced that it has executed definitive agreements for the acquisition of TW & EW Services Inc, a California-based labor and logistics service provider ("TW & EW"). The Acquisition is expected to close on or about December 4, 2024. With TW & EW's integration, Cheetah expects to capitalize on additional service opportunities, and strengthen its position as a comprehensive supply chain solutions provider. The total cost of the Acquisition includes a cash payment of $200,000 and a share consideration involving the issuance of Cheetah's unregistered Class A common stock valued at $800,000, with a per-share price at $1.704. Following the Acquisition, TW & EW will become a wholly owned subsidiary of the Company.(NASDAQ:CTNT)

U.S. announces new export controls on China's chip industry. /pdf/

Nauticus Robotics, Inc., a leading innovator in autonomous subsea robotics and software, recently completed a project for a second global supermajor oil and gas company in the Gulf of Mexico (GOM) to perform a subsea field inspection utilizing its flagship underwater vehicle, Aquanaut Mark 2. (NASDAQ:KITT)

Shares of semiconductor companies are trading higher. The Biden administration plans on limiting China's access to advanced chips, chipmaking tools and memory technology due to alleged national security concerns and AI's military potential. - ARM ADI AMAT AMD ASML AVGO ENPH FORM GFS ICHR JKS KLAC LAES LRCX MCHP MPWR NVTS NXPI ON QCOM SPI SQNS TER TSM WOLF - The outgoing Biden administration will implement its third crackdown on China's semiconductor industry within three years, citing the same national security threats as reasons it mentioned for its prior sanctions, intensifying geopolitical tensions between the countries. The initiative, launching Monday, will impose export restrictions on 140 Chinese entities, including chip equipment manufacturers such as Naura Technology Group and other firms, targeting advanced memory chips and chipmaking tools. Nvidia Corp stock is trading lower on Monday. Prior reports indicated Nvidia's potential to earn $12 billion in sales from 1 million H20 GPUs in China in 2024.

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer.(NASDAQ:PPBT)

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML. Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing. (NASDAQ:SNTI)

AAPL

ARM

AVGO

CDIO

COST

CRKN

FSLR

IONQ

JOBY

KITT

MSFT

NNE

NNOX

NVDA

PACB

PGY

REKR

RR

RXRX

SERV

SOUN

TSLA

TSM

WAVE

WMT

Byte51

Agenda | CME | CPI | FTE | IP | PCE | PMI | PPI | PAYROLL | Sahm | UR | YEN |

* * *